Two proteins are central to Alzheimer’s disease: amyloid-beta, which forms sticky plaques between brain cells, and tau, which tangles up inside neurons and destroys their internal structure. For decades, amyloid-beta was considered the primary cause. The picture now looks more complicated, with growing evidence that amyloid-beta may play a smaller role than originally thought and that tau’s spread through the brain more closely tracks the actual decline in thinking and memory.
Amyloid-Beta: The Plaque-Forming Protein
Amyloid-beta is a small protein fragment created when enzymes called secretases cut apart a larger molecule known as amyloid precursor protein (APP). In a healthy brain, these fragments are produced and cleared away routinely. In Alzheimer’s, the balance tips. Production outpaces clearance, and the fragments, particularly a stickier 42-amino-acid version called Aβ42, begin clumping together outside neurons. These clumps grow into the amyloid plaques visible on brain scans and at autopsy.
Certain genetic mutations in the APP gene or in genes called presenilins ramp up production of Aβ42, which is why some families develop Alzheimer’s at unusually young ages. But in the more common late-onset form, the problem is less about overproduction and more about the brain’s failure to clear the protein efficiently. This buildup begins remarkably early. A person may not show any signs of cognitive trouble for 20 years or more after the first amyloid plaques appear, according to estimates from the National Institute on Aging.
Why Amyloid-Beta May Not Be the Whole Story
The idea that amyloid-beta is the central cause of Alzheimer’s, known as the amyloid cascade hypothesis, has dominated research since the 1980s. It’s an intuitive theory: plaques build up, neurons die, memory fails. But the evidence has grown more ambiguous over time.
One major problem is that plaque levels in the brain don’t correlate well with how impaired someone actually is. Some people die with heavy plaque loads and never developed dementia. Meanwhile, drugs designed to strip amyloid from the brain have shown only modest clinical benefits, slowing decline slightly rather than stopping it. A 2023 review in the journal Brain argued that amyloid-beta may play “a minor role in the aetiology and thus treatment of the disease,” suggesting it could be more of a marker of brain injury than a driver of it. In this view, amyloid buildup is a response to underlying damage rather than the thing causing it.
That said, amyloid-beta hasn’t been dismissed entirely. A revised version of the hypothesis treats it as one important factor among several, rather than the single trigger. The scientific consensus is shifting toward a model where multiple proteins and processes interact to produce the disease.
Tau: The Protein That Tracks With Decline
If amyloid-beta is the protein that defines Alzheimer’s on a scan, tau is the one that seems to track with what patients actually experience. Tau is a normal, essential protein. Its job is to stabilize microtubules, the tiny structural tubes inside neurons that act like highways for transporting nutrients and signals from one end of the cell to the other.
In Alzheimer’s, tau becomes hyperphosphorylated, meaning it gets loaded with too many chemical tags called phosphate groups. This causes it to detach from the microtubules and clump into tangled fibers inside the neuron. Without tau holding them together, the microtubules collapse. The cell’s transport system breaks down, and the neuron eventually dies. Studies in mouse models of Alzheimer’s show reduced microtubule density and impaired transport in neurons filled with these tau tangles.
What makes tau especially dangerous is how it spreads. Misfolded tau moves from cell to cell in a process called seeding, progressing from memory-related brain regions into areas responsible for language, reasoning, and spatial awareness. Research has shown that high tau seeding activity is linked to a faster rate of worsening dementia. The pattern of tau’s spread through the brain maps closely onto the sequence of symptoms patients develop, which is why many researchers now consider tau at least as important as amyloid-beta in driving the disease.
Other Proteins Found in Alzheimer’s Brains
Amyloid-beta and tau are the two defining proteins, but they aren’t always alone. When researchers examine brain tissue from people with Alzheimer’s, they frequently find two additional proteins: alpha-synuclein (more commonly associated with Parkinson’s disease) and TDP-43 (linked to a form of dementia that affects the front and sides of the brain). In one study of clinically normal elderly individuals who came to autopsy, TDP-43 was present in about 22% and alpha-synuclein in about 14%. These co-pathologies likely influence how quickly someone declines and which symptoms are most prominent, adding to the complexity of the disease.
Genetics and Protein Clearance
Your genes influence how well your brain handles these proteins. The most significant genetic risk factor for late-onset Alzheimer’s is a variant of the APOE gene called APOE4. Everyone inherits two copies of APOE, and carrying even one APOE4 copy raises your risk substantially. Carrying two copies raises it even more.
The mechanism is remarkably specific. Normally, amyloid-beta is cleared from the brain through a fast-acting receptor at the blood-brain barrier. APOE4 redirects this process to a much slower receptor, essentially bottlenecking the exit route. In mouse studies, the APOE4 variant increased brain retention of amyloid-beta by 9- to 15-fold compared to unbound amyloid, depending on the form. The APOE2 and APOE3 variants, by contrast, only moderately slow clearance because they can still partially use the faster pathway. This helps explain why APOE4 carriers accumulate plaques earlier and faster.
How Your Brain Clears These Proteins
The brain has its own waste-removal system, sometimes called the glymphatic system, that flushes out metabolic byproducts including amyloid-beta and tau. It works by pumping cerebrospinal fluid through brain tissue along channels that run alongside blood vessels. This system is most active during deep, slow-wave sleep, the dreamless phase when brain waves are slow and synchronized and heart rate is steady.
Research from the University of Rochester found that the synchronized neural firing patterns during deep sleep, which move from the front of the brain to the back, coincide with the flow of cerebrospinal fluid through the glymphatic system. The chemical changes that occur when neurons fire appear to drive a process of osmosis that pulls fluid through brain tissue. When researchers used anesthetics that suppressed slow brain activity in mice, glymphatic function dropped significantly. This has led to speculation that chronic sleep disruption, which is common in aging, could impair waste clearance and contribute to the protein buildup seen in Alzheimer’s.
Detecting These Proteins Early
Until recently, the only ways to detect Alzheimer’s-related proteins were a spinal tap or an expensive PET brain scan. Blood tests are now changing that. Tests measuring a specific form of phosphorylated tau called p-tau217 have shown roughly 90% accuracy at identifying people with Alzheimer’s-related brain changes confirmed by PET imaging or autopsy. Another marker, p-tau181, performs similarly. These tests can flag the disease years before symptoms appear, during the long silent phase when proteins are accumulating but cognition is still intact.
This early detection window matters because it aligns with when interventions, whether pharmaceutical or lifestyle-based, have the best chance of making a difference. The 20-plus-year gap between the first protein deposits and the onset of symptoms represents a period when the brain is compensating but gradually losing ground.